1. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Issue 7 (July 2021) Authors: Burns, Daniel K; Alexander, Robert C; Welsh-Bohmer, Kathleen A; Culp, Meredith; Chiang, Carl; O'Neil, Janet; Evans, Rebecca M; Harrigan, Patrick; Plassman, Brenda L; Burke, James R; Wu, Jingtao; Lutz, Michael W; Haneline, Stephen; Schwarz, Adam J; Schneider, Lon S; Yaffe, Kristine; Saunders, Ann ... Journal: Lancet neurology Issue: Volume 20:Issue 7(2021) Page Start: 537 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗